New industry association president sets priorities in Spain
This article was originally published in Scrip
Executive Summary
An alternative business model for the pharma industry, which is more in tune with the actual needs of health authorities and makes Spain more competitive, is among the priorities of Jesús Acebillo, the new president of the Spanish pharmaceutical industry associationFarmaindustria. He outlined his vision on strengthening the pharmaceutical industry earlier this week during his first public address. Mr Acebillo, president of the NovartisGroup in Spain, said that the industry should act responsibly to keep the national health system sustainable despite the current financial climate, and that better recognition of its innovation and research would continue to be a priority of the association. Mr Acebillo will serve a two-year term, replacing Antoni Esteve, now one of the association's six vice-presidents. The presidency of Farmaindustria rotates between representatives of local and multinational industry.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.